HEALTHQUARTZ
FDA panel overrules its own scientists to ease access to unproven peptide injections
The FDA's Pharmacy Compounding Advisory Committee voted 8-6 to recommend four unproven peptides (BPC-157, KPV, TB-500, and MOTS-c) for access through compounding pharmacies, despite scientific concerns.
Mentioned
Related Signal
Adjacent reporting
- FDA panel votes to add peptides to permitted compounding list despite opposition from agency scientists
- FDA panel votes to add peptides to permitted list despite opposition from agency scientists
- FDA panel narrowly backs unapproved peptide drug touted by Joe Rogan and other influencers
- FDA panel narrowly backs unapproved peptide drug touted by Joe Rogan and other influencers